Teva Pharma (TEVA) Tops Q2 EPS by 2c, Affirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Wall St to open higher on oil retreat, tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
Teva Pharma (TEVA) PT Raised to $11 at Cowen
August 5, 2020 1:04 PM EDTCowen analyst Ken Cacciatore raised the price target on Teva Pharma (NYSE: TEVA) to $11.00 (from $9.00) while maintaining a Market Perform rating.
The analyst commented, "Teva is performing as well as can be expected, with good cost reductions while still executing on the Austedo... More
